ACTIVE	Abaloparatide Comparator Trial In Vertebral Endpoints Trial
ARCH	Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
BMD	Bone mineral density
BMI	Body mass index
BMP	Bone morphogenetic protein
cAMP	cyclic Adenosine monophosphate
ERK1/2	Extracellular-signal Regulated Kinase 1 and 2
FDA	United States Food and Drug Administration
FRAME	Fracture Study in Postmenopausal Women with Osteoporosis
FRAX	Fracture Risk Assessment Score
GIOP	Glucocorticoid-induced osteoporosis
iPTH	Intermittent PTH
LRP5/6	Low-density lipoprotein receptor-related protein 5 or 6
LRP6	Low-density lipoprotein receptor-related protein 6
miRNA	Micro RNA
NBD	NEMO binding domain peptide
NEMO	NF-kappa-B essential modulator
NF-κB	Nuclear factor “kappa-light-chain-enhancer” of activated B-cells
OPG	osteoprotegerin
PTH	Parathyroid hormone
PTH1-34	Teriparatide, peptide Fragment of PTH
PTH1R	parathyroid hormone 1 receptor
PTHrP	parathyroid hormone-related protein
RANK	Receptor Activator of NF-κB
RANKL	Receptor Activator of NF-κB Ligand
rhBMP	Recombinant BMP
Runx2	Runt-related transcription factor 2
Scl	Sclerostin
STRUCTURE	An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
TCF/LEF	T cell factor/lymphoid enhancer factor
Wnt	Wingless-related integration site/Wnt signalling pathway
WT	Wild type